Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 21, 2007; 13(35): 4761-4770
Published online Sep 21, 2007. doi: 10.3748/wjg.v13.i35.4761
Published online Sep 21, 2007. doi: 10.3748/wjg.v13.i35.4761
Table 1 Inhibition of cell growth by NVP-LAQ824 and NVP-LBH589
| Cell line | IC50 (μmol/L) | |||
| NVP-LAQ824 | NVP-LBH589 | |||
| 3 d | 6 d | 3 d | 6d | |
| TFK-1 | 0.06 | 0.05 | 0.01 | 0.01 |
| EGI-1 | 0.07 | 0.05 | 0.01 | 0.01 |
| CC-LP-1 | 0.05 | 0.02 | 0.01 | 0.01 |
| CC-SW-1 | 0.13 | 0.05 | 0.04 | 0.01 |
| Sk-ChA-1 | 0.21 | 0.08 | 0.15 | 0.04 |
| Mz-ChA-1 | 0.14 | 0.07 | 0.09 | 0.04 |
| Mz-ChA-2 | 0.10 | 0.04 | 0.02 | 0.01 |
- Citation: Bluethner T, Niederhagen M, Caca K, Serr F, Witzigmann H, Moebius C, Mossner J, Wiedmann M. Inhibition of histone deacetylase for the treatment of biliary tract cancer: A new effective pharmacological approach. World J Gastroenterol 2007; 13(35): 4761-4770
- URL: https://www.wjgnet.com/1007-9327/full/v13/i35/4761.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i35.4761